Search Results for "Sorafenib Gastric Cancer Asian Phase I Study"
Original Source: Sorafenib Gastric Cancer Asian Phase I Study
This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.
Matching Channels
The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...
ETS2101 (dexanabinol) is a synthetic cannabinoid previously studied in trauma patients. Its anti-cancer potential was identified by e-Therapeutics’ network pharmacology platform. This revealed...
Epithelial cell adhesion molecule EpCAM CD326
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian,...
Matching News
Optimal Screening Interval for Gastric Cancer: 3 Years
This Asian study of adults newly diagnosed with gastric cancer might not apply in the United States and Europe, say authors. Medscape Medical News
Scientists at the Genome Institute of Singapore (GIS) headed a study which culminated in the discovery of four processes by which gastric cancer is formed. With gastric cancer being the second most co...
Study determines optimal screening strategy for gastric or stomach cancer
A new study has determined how often people should get screened for gastric or stomach cancer in high-risk regions of the world. Published early online in CANCER, a peer-reviewed journal of the Americ...
Four Distinct Mechanisms Identified That Contribute To Gastric Cancers
Scientists at A*STAR's Genome Institute of Singapore (GIS) headed a study that discovered four processes by which gastric cancer is formed. This is extremely important since gastric cancer is the seco...
Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer
Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of C...
Scientists discover four processes by which gastric cancer is formed
Scientists at A*STAR's Genome Institute of Singapore (GIS) headed a study that discovered four processes by which gastric cancer is formed. This is extremely important since gastric cancer is the seco...
Researchers identify four distinct mechanisms that contribute to gastric cancers
Scientists at A*STAR's Genome Institute of Singapore (GIS) headed a study that discovered four processes by which gastric cancer is formed. This is extremely important since gastric cancer is the seco...
Erbitux fails in Phase III EXPAND gastric cancer trial
Merck Serono says that its cancer treatment Erbitux (cetuximab) failed to meet its primary endpoint in the Phase III EXPAND trial in patients with advanced gastric cancer, dealing the company yet anot...
Matching PubMed Articles
BACKGROUND: Sorafenib inhibits several receptor tyrosine kinases involved in tumor progression and angiogenesis. S-1, an oral fluorouracil antitumor drug, plus cisplatin (CDDP) is the standard regimen...
Background To define maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary efficacy of sorafenib plus capecitabine/cisplatin in advanced gastric cancer (AGC) patients. Methods...
Hepatocellular carcinoma (HCC) is common in Asia, and there were no effective chemotherapeutic agents for advanced HCC. Sorafenib, an oral multikinase inhibitor, has set a milestone in the management...
Background Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-beta, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic c...
Purpose Patients with metastatic pancreatic cancer have limited therapeutic options. The role of the Ras-Raf-MAPK pathway and of vascular endothelial growth factor in pancreatic carcinogenesis provide...
